Toggle menu

PitSTOP

Start date:
August 2017
End date:
August 2018
Co-ordinated by:
Dr John Emelifeonwu and the EMERGE Team, RIE
Main trial site:
RIE

Primary Objective
To determine the prevalence of anterior pituitary gland dysfunction in traumatic brain injury in Scotland.

Secondary Objectives
To determine whether clinical and radiologically parameters available on presentation can predict likelihood of developing PTPD in patients with TBI.
To determine the optimal timing after TBI for blood tests to diagnose PTPD
To determine whether PTPD effects functional recovery as determined by the extended Glasgow Outcome Score (eGOS)

Chief Investigator

Dr John Emelifeonwu

Surgical Trainee, Clinical Neurosciences

Research Team

Mia Paderanga

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

MAPP2 Study

The Markers and Paracetamol Poisoning Study 2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)